Eiger BioPharmaceuticals, Inc. EIGRQ

8.50 0.00 0.00% as of 1 Oct
Market cap
$2.6M
P/E
0.0×
Growth Flags show if company had growth for consecutive years
Older periods Mar '23 Jun '23 Sep '23 Dec '23
ROE

+8 more TTM periods

(146.28%) (161.95%) (225.93%) (367.00%)
ROA
(76.75%) (81.11%) (86.91%) (94.31%)
ROIC
(14,894.98%) (2,469.33%) 0.00% (3,674.55%)
Return on Tangible Assets
(131.47%) (175.56%) (223.45%) 505.89%
Average Days of Receivables
95.13 87.59 32.88 38.92
Free Cash Flow per Share
(60.62) (60.61) (56.44) (50.67)
Free Cash Flow
(89.11) (89.41) (83.30) (74.78)
Capital Expenditures
(0.56) (0.56) (0.46) (0.23)
Piotroski F-Score
3.00 2.00 3.00 3.00
Other line items
Cash ROIC
(58.67%) (81.08%) (105.19%) (143.08%)
Accounts Receivable Turnover
4.83 6.51 7.76 9.19
Accounts Payable Turnover
0.18 0.19 0.03 0.00
Inventory Turnover
0.51 0.70 0.14 0.01
Average Days of Payables
2,345.89 1,304.40 6,616.31 32,165.63
Days of Inventory on Hand
1,056.03 289.57 1,504.94 23,664.17
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
498.76% 496.53% 472.10% 395.18%
Selling, General and Administrative Expense of Revenue
213.06% 195.81% 196.39% 159.79%
Share Based Compensation of Revenue
59.03% 47.47% 42.04% 31.75%
Interest Coverage
0.00 0.00 0.00 0.00
Operating CF/Net income
0.91 0.93 0.96 0.99
Depreciation/Fixed assets
0.34 (0.50) (1.14) (1.33)
Capex/Depreciation
(2.05) 1.51 0.59 0.28
Revenue per Share
10.16 10.49 9.94 10.69
Operating CF per Share
(60.24) (60.23) (56.13) (50.51)
Capex per Share
(0.38) (0.38) (0.31) (0.16)
Capex to Sales
0.04 0.04 0.03 0.01
Net Profit Margin
(649.19%) (618.36%) (590.80%) (475.26%)

Fold the line items

Columns are period end dates